I-MAB (IMAB) Growth Rank : 0 (As of Mar. 31, 2025)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Growth Rank?

I-MAB has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

I-MAB Growth Rank Related Terms

Thank you for viewing the detailed overview of I-MAB's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850

Website

https://www.i-mabbiopharma.com

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).